Non-Clinical Evidence Supporting the Upcoming CLD-201 Clinical Trial: Cell-Based Oncolytic Virotherapy for Multiple Solid Tumors
ASCO Annual Meeting 2024
Event
NeuroNova & SuperNova
Stem Cell Platforms for Enhanced Oncolytic Virotherapy
Festival of Biologics
Event
SuperNova & NeuroNova
Deciphering Anticancer Mechanisms of Oncolytic Virus-loaded Stem Cells
American Association for Cancer Research
Event
SuperNova
Annual Meeting – SITC 2023 – Nov 1st to 5th 2023 in San Diego, CA, USA.
SUPERNOVA1 (SNV1), A NOVEL ONCOLYTIC-CELL BASED PLATFORM FOR CANCER THERAPY
Publication
SuperNova
Development of Allogeneic Stem Cell-Based Platform for Delivery and Potentiation of Oncolytic Virotherapy
National Center for Biotechnology Information
publications
SuperNova
Abstract 4473: Evaluation of the potential of oncolytic vaccinia virus delivered by autologous SVF to modulate innate and adaptive immunity in patients with diverse solid and hematological malignancies
American Association for Cancer Research
publications
SuperNova
Abstract 6542: CAL1 vaccinia virus as oncolytic agent and potential use of cell-based platform to enhance its therapeutic effects
American Association for Cancer Research
Publication
SuperNova
Enhancement of the therapeutic effects of oncolytic vaccinia virus by using autologous and allogeneic cell-based delivery platforms.
Journal of Clinical Oncology
Publication
SuperNova
A cell-based platform to potentiate oncolytic virus: Potential approach for cancer therapies.
Journal of Clinical Oncology
publications
SuperNova
A cell-based platform to potentiate oncolytic virus: Potential approach for cancer therapies.
Journal of Clinical Oncology
Publication
SuperNova
First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells
The Journal of Translational Medicine
Publication
SuperNova
Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers
